Deval Patrick Says He Might Run for President
Patrick, who's nearing the end of his eight-year run as governor, made the comments in an interview with WCVB.
WCVB reported Patrick made the comments during a taping of its show “ On the Record.”
“There are a lot of people who have asked me to think about (running for president),” Patrick said. “It’s a huge decision, not just for me but for my family.”
When asked if he would indeed run, Patrick said, “Maybe, but not right away.”
Patrick, 58, is nearing the end of his second term as governor. He’s not running for re-election. Massachusetts does not have term limits for the governor’s office.
Patrick is a former civil rights lawyer at the Department of Justice and served as legal counsel for companies like Coca-Cola and Texaco. He has a close relationship with President Obama.
In 2011, Patrick told the State House News Service he’d consider running a company when his run as governor was up.
After he was elected governor in 2006, Patrick said he considered resigning because of the toll the campaign took on his wife, Diane, who was treated for depression.
Before the Reverse Split if a Phase III Approval had taken place, the stock could have possibly jumped from $0.40 a share up into the $1's, $2's or $3's. So stockholders should not be surprised if the price per share in its current valuation was to skyrocket with FDA Approval.
Of this I am fairly sure and the response may not happen all in one day with the news, but during the following weeks. Even $50 or $100 a share eventually would not surprise me and those of us who have held the stock prior to the Reverse Split.
I stepped away from the computer in the later part of the trading day. When I returned I was pleased to see a considerable lift encouraged by the two largest trades of the day which occurred at the close. Wishing an enjoyable weekend to all the ZIOPHARM Oncology Longs.
Roger L. Hawley is a Co-Founder of Zogenix Inc., and has been its Chief Executive Officer since August 2006. According to Bloomberg his Total Calculated Compensation is $1.8M annually.
Tocqueville Asset Management Takes 8.73% Stake in Inuvo
6:34 AM ET, 07/11/2014
In a 13D filing on Inuvo, Inc. (NYSE: INUV), hedge fund Tocqueville Asset Management disclosed a 8.73%, or 1,902,800 share, stake in the company. The firm did not hold shares at the end of the latest quarter ending March 31, 2014.
More from the 13D:
The Reporting Person acquired the Shares of the Issuer for investment purposes. The Reporting Person evaluates the investment in the Shares on a continual basis.
The Reporting Person has no plans or proposals as of the date of this filing which relate to, or would result in, any of the actions enumerated in Item 4 of the instructions to Schedule 13D.
Charles Morgan, who is an investor in a client of the Reporting Person, serves as a director of the Issuer.
Mylan is being honored for its charitable giving to WVU and commitment to enhance the areas and people it serves.
The West Virginia University Foundation has announced the recipients of its 2014 Outstanding Philanthropy awards.
Heather Bresch is chief executive officer of Mylan, one of the largest generics and specialty pharmaceutical companies in the world.
West Virginia University Provost Gerald Lang has resigned in the face of criticism over his handling of a master's degree improperly awarded to governor Joe Manchin’s daughter.
A panel appointed by WVU and featuring independent educators from New York, Missouri and Pennsylvania has been investigating how discrepancies about Ms. Bresch's degree were handled by school administrators in October. It has yet to release its conclusions.
The appointment of the panel was sparked by a Dec. 21 story by the Post-Gazette that raised questions about how the university awarded the degree to Ms. Bresch, despite records that showed she had completed only about half of the credits needed to earn the degree.
Ms. Bresch has repeatedly declined to comment to the Post-Gazette about questions surrounding her degree. She could not be reached for comment last night.
A buyout is always possible, but I was responding to the message posted mentioning that Zogenix will be acquired because the company cannot afford the cost of having Zohydro formulated into being tamper proof.
Please refrain from talking out of your rear end as the Altus Formulation cost is easily affordable:
Under the D&O Agreement, Altus has granted Zogenix an option (subject to the terms and conditions of the D&O Agreement) to enter into an exclusive license on mutually agreed terms to develop and commercialize abuse deterrent formulations of Zohydro ER in the United States. In connection with the transaction, Zogenix will pay Altus a technology access fee in the amount of $750,000. Zogenix will fund all development activities, and Altus may earn up to an additional $3.5 million in development and regulatory milestones through submission of a New Drug Application (NDA) under the D&O Agreement. Following exercise of the option, Altus will be eligible to receive additional undisclosed regulatory and sales milestone payments and a royalty based on net sales of the licensed product.
That would have to happen during the next 3 1/2 hours of trading tomorrow Thursday with the early close and that is highly doubtful with this Friday being a holiday unless you are talking about the following Friday and you will be broke and gone from this message board by that time if you are short.